Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 25 results found. Search for [ Amgen ]

Results 1 to 21 of 25
Reuters
December 22, 2020
Shares of Apple Inc were up 3.8% in early trading after Reuters exclusively reported that the company was moving forward with self-driving car technology and was targeting 2024 to produce a passenger vehicle


Reuters
October 9, 2020
Lilly had previously said it would make one million doses of its single antibody treatment available by the end of the year


BusinessToday.In
August 30, 2020
The reason why Exxon's stock has plunged is for more than the simple fact that oil has fallen out of favour by investors


Rupa Burman Roy
July 20, 2020
Sectorally, barring pharma, all other sectors closed in green territory, with IT index ending 2.6% and banking indices closing 1.5% higher


E Kumar Sharma
New Delhi, November 25, 2019
A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?


E Kumar Sharma
New Delhi, July 24, 2019
Analysts expect a better show in Q1 thanks to a combination of factors such as overall business improvement in the Unites States and a pick-up in demand in the domestic market.


PTI
May 3, 2019



PTI
March 12, 2019



PTI
March 6, 2019



PB Jayakumar
New Delhi, January 9, 2019
Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide


PB Jayakumar
December 19, 2018
Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.


PB Jayakumar
New Delhi, February 21, 2018
The competition to tap large molecule structured complex bio-similars or off-patent biotech drugs is heating up.


E Kumar Sharma
New Delhi, September 15, 2017
India has taken a lead here and going by the official figures, there are around 24 cancer biosimilar drugs in all that have already been approved by the Indian regulator since 2011.


By E. Kumar Sharma
Delhi, July 23, 2016
Indian drug makers are slugging it out with Big Pharma over launch of biosimilars. Will they be able to hold their fort in this emerging space?


Reuters
New York, March 1, 2016
Stocks and oil have been strongly correlated in recent months as crude prices tanked to decade lows, and their movements in opposite directions during the session was notable to investors.


E Kumar Sharma
February 11, 2016
There is pressure by some sections within the US to downgrade India from 'watch list' to 'Priority foreign country'.


E Kumar Sharma
October 29, 2015
The profit for the second quarter period crossed Rs 700 crore. According to analysts, these were a good set of numbers given the challenges and the fact that it did not take any price hikes.


IANS
New Delhi, September 14, 2015
The exclusive rights for this product are applicable for the US, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.


Neetu Chandra Sharma
New Delhi, August 7, 2015
Drug Controller General Dr GN Singh directed officials to compile list of veterinary drugs with details like date of approval, name of manufacturer, composition of product and its storage conditions.


E Kumar Sharma
August 6, 2015
It is still not clear who is severely impacted by the ban. Because if the impact was huge on any company, it would have by now informed the stock exchanges.


PAGES 1 OF 2  12